X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1733) 1733
animals (938) 938
male (937) 937
purinergic p2y receptor antagonists - therapeutic use (828) 828
platelet aggregation inhibitors - therapeutic use (701) 701
female (688) 688
clopidogrel (635) 635
ticlopidine - analogs & derivatives (592) 592
middle aged (484) 484
adenosine - analogs & derivatives (450) 450
aged (450) 450
ticlopidine - therapeutic use (435) 435
cardiac & cardiovascular systems (427) 427
pharmacology & pharmacy (419) 419
percutaneous coronary intervention (404) 404
atp (392) 392
treatment outcome (392) 392
ticagrelor (362) 362
prasugrel (324) 324
adenosine - therapeutic use (323) 323
acute coronary syndrome - drug therapy (322) 322
neurosciences (316) 316
purinergic p2y receptor antagonists - adverse effects (316) 316
acute coronary syndromes (314) 314
rats (303) 303
platelet aggregation inhibitors - adverse effects (300) 300
blood platelets - drug effects (291) 291
prasugrel hydrochloride (265) 265
aspirin (264) 264
platelet aggregation - drug effects (263) 263
mice (257) 257
purinergic p2y receptor antagonists - administration & dosage (255) 255
purinergic p2y receptor antagonists - pharmacology (249) 249
aspirin - therapeutic use (248) 248
purinergic p2 receptor antagonists (246) 246
abridged index medicus (244) 244
adenosine (242) 242
platelet aggregation inhibitors - pharmacology (242) 242
platelet aggregation inhibitors - administration & dosage (232) 232
adenosine triphosphate - pharmacology (228) 228
receptors, purinergic p2 - metabolism (220) 220
risk factors (214) 214
dose-response relationship, drug (211) 211
hematology (199) 199
acute coronary syndrome (198) 198
antiplatelet therapy (197) 197
peripheral vascular disease (195) 195
blood platelets - metabolism (194) 194
analysis (193) 193
piperazines - therapeutic use (193) 193
thiophenes - therapeutic use (193) 193
drug therapy, combination (190) 190
cell biology (189) 189
cardiovascular (184) 184
adenosine triphosphate - metabolism (182) 182
hemorrhage - chemically induced (181) 181
thrombosis (178) 178
inflammation (177) 177
inhibition (176) 176
purinergic receptors (175) 175
time factors (174) 174
p2y (170) 170
prospective studies (168) 168
care and treatment (167) 167
activation (166) 166
blood platelets (166) 166
signal transduction (163) 163
extracellular atp (162) 162
coronary heart disease (160) 160
heart attacks (158) 158
cardiac patients (154) 154
platelet function tests (154) 154
ticlopidine - adverse effects (154) 154
cardiology (153) 153
adult (151) 151
research (151) 151
receptors, purinergic p2 - physiology (149) 149
biomedicine (146) 146
myocardial-infarction (145) 145
receptors (145) 145
cells, cultured (143) 143
drug therapy (142) 142
adenosine triphosphate - analogs & derivatives (138) 138
physiology (138) 138
pharmacology/toxicology (136) 136
ticlopidine - administration & dosage (136) 136
rats, sprague-dawley (134) 134
stents (133) 133
myocardial infarction - drug therapy (132) 132
mortality (128) 128
ticlopidine - pharmacology (127) 127
p2x receptor (125) 125
adenosine - pharmacology (122) 122
platelets (122) 122
biochemistry & molecular biology (121) 121
aggregation (120) 120
adenosine - adverse effects (119) 119
p2x receptors (119) 119
rodents (119) 119
p2y receptor (118) 118
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2395) 2395
German (20) 20
French (12) 12
Russian (8) 8
Italian (5) 5
Spanish (5) 5
Polish (3) 3
Japanese (2) 2
Portuguese (2) 2
Turkish (2) 2
Chinese (1) 1
Hungarian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England journal of medicine, ISSN 1533-4406, 2017, Volume 377, Issue 16, pp. 1513 - 1524
In this trial, dabigatran plus a P2Y 12 inhibitor was compared with warfarin plus a P2Y 12 inhibitor and aspirin after PCI in patients with atrial fibrillation... 
MEDICINE, GENERAL & INTERNAL | PERCUTANEOUS CORONARY INTERVENTION | HEART-DISEASE | MYOCARDIAL-INFARCTION | ORAL ANTICOAGULATION | 2011 ACCF/AHA/SCAI GUIDELINE | AMERICAN-COLLEGE | ASSOCIATION TASK-FORCE | TRIPLE THERAPY | ANTIPLATELET THERAPY | CONSENSUS DOCUMENT | Dabigatran - adverse effects | Ticlopidine - therapeutic use | Humans | Middle Aged | Warfarin - adverse effects | Male | Risk | Dabigatran - therapeutic use | Incidence | Warfarin - therapeutic use | Purinergic P2Y Receptor Antagonists - adverse effects | Drug Therapy, Combination - adverse effects | Adenosine - adverse effects | Adenosine - therapeutic use | Female | Aspirin - therapeutic use | Platelet Aggregation Inhibitors - therapeutic use | Ticagrelor | Purinergic P2Y Receptor Antagonists - therapeutic use | Hemorrhage - epidemiology | Atrial Fibrillation - drug therapy | Atrial Fibrillation - therapy | Anticoagulants - therapeutic use | Anticoagulants - adverse effects | Ticlopidine - analogs & derivatives | Adenosine - analogs & derivatives | Clopidogrel | Aged | Hemorrhage - chemically induced | Percutaneous Coronary Intervention | Warfarin | Atrial fibrillation | Dosage and administration | Research | Thromboembolism | Hemorrhage | Health aspects | Myocardial infarction | Cerebral infarction | Cardiac arrhythmia | Anticoagulants | Aspirin | Stroke | Embolisms | Preventive medicine | Thrombosis | Bleeding | Embolism | Fibrillation | Cardiology | Drug therapy | Drug dosages | Geriatrics
Journal Article
Neuropharmacology, ISSN 0028-3908, 2016, Volume 104, pp. 31 - 49
...), P2Y and P2X receptors. We present a selection of the most commonly used agents to study purines in the nervous system... 
Nucleosides | GPCR | Agonists | Antagonists | Nucleotides | Ion channel | ATP | PROTEIN-COUPLED RECEPTORS | ALLOSTERIC MODULATION | NEUROSCIENCES | NEUROPATHIC PAIN | NUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE | IN-VIVO | ION-CHANNEL | PHARMACOLOGY & PHARMACY | CENTRAL-NERVOUS-SYSTEM | PURINERGIC RECEPTOR | P2Y RECEPTOR | STRUCTURE-BASED DESIGN | Purinergic P1 Receptor Agonists - chemistry | Receptors, Purinergic P2Y - chemistry | Receptors, Purinergic P2X - chemistry | Humans | Purinergic P1 Receptor Agonists - pharmacology | Receptors, Purinergic P2Y - metabolism | Purinergic P1 Receptor Antagonists - therapeutic use | Purinergic P2Y Receptor Agonists - chemistry | Purinergic P2Y Receptor Agonists - therapeutic use | Structure-Activity Relationship | Purinergic P1 Receptor Agonists - therapeutic use | Chemistry, Pharmaceutical | Purinergic P1 Receptor Antagonists - pharmacology | Purinergic P2Y Receptor Agonists - pharmacology | Receptors, Purinergic P1 - chemistry | Animals | Purinergic Agents - chemistry | Purinergic Agents - therapeutic use | Receptors, Purinergic P2X - metabolism | Receptors, Purinergic P1 - metabolism | Purinergic Agents - pharmacology | Purinergic P1 Receptor Antagonists - chemistry | Prevention | Brain | Purines | Enzymes | Injuries | Chronic pain | Cancer | antagonists | nucleosides | agonists | ion channel | nucleotides
Journal Article
International journal of molecular sciences, ISSN 1422-0067, 2014, Volume 15, Issue 12, pp. 23672 - 23704
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2016, Volume 375, Issue 25, pp. 2423 - 2434
... – 3 Dual antiplatelet therapy (DAPT) with a P2Y 12 inhibitor and aspirin is superior to oral anticoagulation with a vitamin K antagonist in reducing the risk of thrombosis in patients undergoing placement of a first-generation stent, 4... 
MEDICINE, GENERAL & INTERNAL | PERCUTANEOUS CORONARY INTERVENTION | THERAPY | RIVAROXABAN | OPEN-LABEL | ANTITHROMBOTIC STRATEGIES | ANTICOAGULATION | Confidence Intervals | Humans | Middle Aged | Male | Hemorrhage - prevention & control | Rivaroxaban - administration & dosage | Factor Xa Inhibitors - administration & dosage | Purinergic P2Y Receptor Antagonists - adverse effects | Vitamin K - antagonists & inhibitors | Rivaroxaban - adverse effects | Cardiovascular Diseases - epidemiology | Cardiovascular Diseases - mortality | Female | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Stents | Purinergic P2Y Receptor Antagonists - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Atrial Fibrillation - drug therapy | Atrial Fibrillation - therapy | Kaplan-Meier Estimate | Factor Xa Inhibitors - adverse effects | Aged | Hemorrhage - chemically induced | Percutaneous Coronary Intervention | Prevention | Complications and side effects | Angiography | Atrial fibrillation | Hemorrhage | Patients | Health aspects | Myocardial infarction | Cerebral infarction | Cardiac arrhythmia | Anticoagulants | Aspirin | Stroke | Angioplasty | Coagulation | Thrombosis | Thrombolysis | Bleeding | Fibrillation | Implants | Vitamin K
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2016, Volume 375, Issue 1, pp. 35 - 43
Journal Article
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 2014, Volume 64, Issue 10, pp. 1005 - 1014
Journal Article